Mission

CCRM was founded in Canada as an industry consortium of diverse companies that aim to develop products applying regenerative medicine technologies to biomedicine. Regenerative medicine is a discipline that harnesses the power of stem cells, biomaterials, and molecules to repair, regenerate, or replace diseased cells, tissues, and organs, to treat, manage, and cure disease.
 
CCRM aims to enable new opportunities and address shared bottlenecks in the advancement of regenerative medicine. The consortium provides market orientation and a ready supply of global receptors for technologies and products generated by CCRM. CCRM’s mission is to create and sustain a global nexus for regenerative medicine commercialization by unifying dynamic business leadership with high-value innovative translational technology platforms based on demonstrated excellence in fundamental stem cell and biomaterial science.

Structure & Governance

Founding Institutional Members:

Building on world-leading strengths in stem cell research and biomaterials, researchers across six regenerative medicine centers in Ontario have come together in a coordinated, collaborative fashion to support CCRM’s creation. The institutions represent a significant investment in infrastructure and research capacity related to regenerative medicine activity in Ontario: Hospital for Sick Children Research Institute, Toronto; McMaster University, Hamilton; Mount Sinai Hospital Samuel Lunenfeld Research Institute, Toronto; Ottawa Hospital Research Institute, Ottawa; University Health Network, Toronto; University of Toronto, Toronto.

CCRM’s Board of Directors represents extensive experience in company creation, international academic excellence, and seasoned leaders sourced from the regenerative medicine industry. Current members include Gregory Bonfiglio, Proteus Venture Partners (chair); Allen Eaves, STEMCELL Technologies Inc., Canada; Rafi Hofstein, MaRS Innovation; Peter Lewis, University of Toronto; Geoff MacKay, Organogenesis; Michael May, Centre for Commercialization of Regenerative Medicine; Stephen Minger, GE Healthcare; Gail Naughton, Histogen Inc.; Christopher Paige, University Health Network; David Smith, Lonza; Susan L. Solomon, New York Stem Cell Foundation; Duncan Stewart, Ottawa Hospital Research Institute; Peter Zandstra, Centre for Commercialization of Regenerative Medicine.

The Strategic Advisory Board (SAB) is composed of world-leading experts in stem cell and biomaterials technologies. CCRM shares its SAB with the Ontario Stem Cell Initiative (OSCI). Current co-chairs are
Janet Rossant, Hospital for Sick Children Research Institute, Canada, and Peter Zandstra, Centre for Commercialization of Regenerative Medicine, Canada. SAB members include George Daley, Children’s Hospital Harvard; Jeffrey Hubbell, École Polytechnique Fédérale de Lausanne; Douglas Lauffenburger, Massachusetts Institute of Technology; Chris Mason, University College London; Shin-Ichi Nishikawa, Riken Centre for Developmental Biology; Kathrin Plath, University of California; Michael Sefton, University of Toronto; Toshio Suda, Keio University; Jakub Tolar, University of Minnesota; Fiona Watt, King’s College London; Shinya Yamanaka, Centre for iPS Cell Research and Application (honorary member).

Lead Scientists and Founders Advisory Board:

CCRM staff working in each of the translational platforms can access feedback and guidance from the lead scientists. Bill Stanford and James Ellis are the lead scientists for the Cell Reprogramming & Engineering Platform. Gordon Keller and Mick Bhatia are the lead scientists for the Cell Manufacturing Platform. Molly Shoichet is the lead scientist for the Biomaterials & Devices Platform.

The chief scientific officer and the lead scientists, together with key CCRM members form the Founders Advisory Board (FAB). The roles of FAB are to provide guidance, contacts, and environment scanning for CCRM activities and to act in an advisory capacity for CCRM operations. Current members include Mick Bhatia, McMaster Stem Cell and Cancer Research Institute; James Ellis, The Hospital for Sick Children Research Institute; Armand Keating, University Health Network; Gordon Keller, McEwen Centre for Regenerative Medicine, University Health Network; Andras Nagy, Samuel Lunenfeld Research Institute, Mount Sinai Hospital; Janet Rossant, The Hospital for Sick Children Research Institute; Michael Rudnicki, Ottawa Hospital Research Institute; Paul Santerre, Institute of Biomaterials & Biomedical Engineering, University of Toronto; Molly Shoichet, Institute of Biomaterials & Biomedical Engineering, University of Toronto; Bill Stanford, Ottawa Hospital Research Institute; Peter Zandstra, Centre for Commercialization of Regenerative Medicine.

Commercialization Review Committee:

The CCRM team continues to actively search for high potential regenerative medicine assets, primarily within its member institutions, as well as globally.
 
The function of the Commercialization Review Committee (CRC) is to review and recommend technologies and projects for investment by CCRM, the business cases for the regenerative medicine assets, and in-licensing and commercialization strategies for focused commercial development of technology. CRC is composed of industry experts, members of the Board of Directors, representatives from the industry consortium, and staff of member technology transfer offices, and it is chaired by Devyn Smith, Ph.D.

Links/Social Media Feed

Points of Contact

CCRM
The Banting Institute
Suite 110-100 College Street
Toronto, ON M5G 1L5 Canada
phone: 416-978-3751

Sponsors & Partners